Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

Zsolt Szabo; Esther Mena; Steven P. Rowe; Donika Plyku; Rosa Nidal; Mario A. Eisenberger; Emmanuel S. Antonarakis; Hong Fan; Robert F. Dannals; Ying Chen; Ronnie C. Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y. Cho; Martin G. Pomper

doi:10.1007/s11307-015-0850-8

Initial Evaluation of [¹⁸F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

Zsolt Szabo, Esther Mena, Steven P. Rowe, Donika Plyku, Rosa Nidal, Mario A. Eisenberger, Emmanuel S. Antonarakis, Hong Fan, Robert F. Dannals, Ying Chen, Ronnie C. Mease, Melin Vranesic, Akrita Bhatnagar, George Sgouros, Steve Y. Cho, Martin G. Pomper

School of Medicine

Research output: Contribution to journal › Article › peer-review

238 Scopus citations

Abstract

Purpose: Prostate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [¹⁸F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer. Procedures: Biodistribution was evaluated using sequential positron-emission tomography (PET) scans in nine patients with prostate cancer. Time-activity curves from the most avid tumor foci were determined. The radiation dose to selected organs was estimated using OLINDA/EXM. Results: No major radiotracer-specific adverse events were observed. Physiologic accumulation was observed in known sites of PSMA expression. Accumulation in putative sites of prostate cancer was observed (SUV_max up to >100, and tumor-to-blood ratios up to >50). The effective radiation dose from [¹⁸F]DCFPyL was 0.0139 mGy/MBq or 5 mGy (0.5 rem) from an injected dose of 370 MBq (10 mCi). Conclusions: [¹⁸F]DCFPyL is safe with biodistribution as expected, and its accumulation is high in presumed primary and metastatic foci. The radiation dose from [¹⁸F]DCFPyL is similar to that from other PET radiotracers.

Original language	English (US)
Pages (from-to)	565-574
Number of pages	10
Journal	Molecular Imaging and Biology
Volume	17
Issue number	4
DOIs	https://doi.org/10.1007/s11307-015-0850-8
State	Published - Aug 23 2015

Keywords

Fluorine-18
Molecular imaging
PET
PSMA
Prostate cancer

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1007/s11307-015-0850-8

Cite this

Szabo, Z., Mena, E., Rowe, S. P., Plyku, D., Nidal, R., Eisenberger, M. A., Antonarakis, E. S., Fan, H., Dannals, R. F., Chen, Y., Mease, R. C., Vranesic, M., Bhatnagar, A., Sgouros, G., Cho, S. Y., & Pomper, M. G. (2015). Initial Evaluation of [¹⁸F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Molecular Imaging and Biology, 17(4), 565-574. https://doi.org/10.1007/s11307-015-0850-8

Szabo, Z, Mena, E, Rowe, SP, Plyku, D, Nidal, R, Eisenberger, MA, Antonarakis, ES, Fan, H, Dannals, RF, Chen, Y, Mease, RC, Vranesic, M, Bhatnagar, A, Sgouros, G, Cho, SY & Pomper, MG 2015, 'Initial Evaluation of [¹⁸F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer', Molecular Imaging and Biology, vol. 17, no. 4, pp. 565-574. https://doi.org/10.1007/s11307-015-0850-8

@article{6015e3e8cd3a45db89e3ad0ae37a76dc,

title = "Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer",

abstract = "Purpose: Prostate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [18F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer. Procedures: Biodistribution was evaluated using sequential positron-emission tomography (PET) scans in nine patients with prostate cancer. Time-activity curves from the most avid tumor foci were determined. The radiation dose to selected organs was estimated using OLINDA/EXM. Results: No major radiotracer-specific adverse events were observed. Physiologic accumulation was observed in known sites of PSMA expression. Accumulation in putative sites of prostate cancer was observed (SUVmax up to >100, and tumor-to-blood ratios up to >50). The effective radiation dose from [18F]DCFPyL was 0.0139 mGy/MBq or 5 mGy (0.5 rem) from an injected dose of 370 MBq (10 mCi). Conclusions: [18F]DCFPyL is safe with biodistribution as expected, and its accumulation is high in presumed primary and metastatic foci. The radiation dose from [18F]DCFPyL is similar to that from other PET radiotracers.",

keywords = "Fluorine-18, Molecular imaging, PET, PSMA, Prostate cancer",

author = "Zsolt Szabo and Esther Mena and Rowe, {Steven P.} and Donika Plyku and Rosa Nidal and Eisenberger, {Mario A.} and Antonarakis, {Emmanuel S.} and Hong Fan and Dannals, {Robert F.} and Ying Chen and Mease, {Ronnie C.} and Melin Vranesic and Akrita Bhatnagar and George Sgouros and Cho, {Steve Y.} and Pomper, {Martin G.}",

note = "Funding Information: Prostate Cancer Foundation–Young Investigator Award, The Patrick C. Walsh Prostate Cancer Research Fund, EB006351, CA134675, CA184228, CA103175, CA183031. Funding Information: We are grateful for the efforts of Yavette Morton and Akimosa Jeffrey-Kwanisai in helping to coordinate this study. We acknowledge the financial support from the Prostate Cancer Foundation–Young Investigator Award, The Patrick C. Walsh Prostate Cancer Research Fund, EB006351, CA134675, CA184228, CA103175, CA183031, and CA116477. Publisher Copyright: {\textcopyright} 2015, World Molecular Imaging Society.",

year = "2015",

month = aug,

day = "23",

doi = "10.1007/s11307-015-0850-8",

language = "English (US)",

volume = "17",

pages = "565--574",

journal = "Molecular Imaging and Biology",

issn = "1536-1632",

publisher = "Springer New York",

number = "4",

}

TY - JOUR

T1 - Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

AU - Szabo, Zsolt

AU - Mena, Esther

AU - Rowe, Steven P.

AU - Plyku, Donika

AU - Nidal, Rosa

AU - Eisenberger, Mario A.

AU - Antonarakis, Emmanuel S.

AU - Fan, Hong

AU - Dannals, Robert F.

AU - Chen, Ying

AU - Mease, Ronnie C.

AU - Vranesic, Melin

AU - Bhatnagar, Akrita

AU - Sgouros, George

AU - Cho, Steve Y.

AU - Pomper, Martin G.

N1 - Funding Information: Prostate Cancer Foundation–Young Investigator Award, The Patrick C. Walsh Prostate Cancer Research Fund, EB006351, CA134675, CA184228, CA103175, CA183031. Funding Information: We are grateful for the efforts of Yavette Morton and Akimosa Jeffrey-Kwanisai in helping to coordinate this study. We acknowledge the financial support from the Prostate Cancer Foundation–Young Investigator Award, The Patrick C. Walsh Prostate Cancer Research Fund, EB006351, CA134675, CA184228, CA103175, CA183031, and CA116477. Publisher Copyright: © 2015, World Molecular Imaging Society.

PY - 2015/8/23

Y1 - 2015/8/23

N2 - Purpose: Prostate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [18F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer. Procedures: Biodistribution was evaluated using sequential positron-emission tomography (PET) scans in nine patients with prostate cancer. Time-activity curves from the most avid tumor foci were determined. The radiation dose to selected organs was estimated using OLINDA/EXM. Results: No major radiotracer-specific adverse events were observed. Physiologic accumulation was observed in known sites of PSMA expression. Accumulation in putative sites of prostate cancer was observed (SUVmax up to >100, and tumor-to-blood ratios up to >50). The effective radiation dose from [18F]DCFPyL was 0.0139 mGy/MBq or 5 mGy (0.5 rem) from an injected dose of 370 MBq (10 mCi). Conclusions: [18F]DCFPyL is safe with biodistribution as expected, and its accumulation is high in presumed primary and metastatic foci. The radiation dose from [18F]DCFPyL is similar to that from other PET radiotracers.

AB - Purpose: Prostate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [18F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer. Procedures: Biodistribution was evaluated using sequential positron-emission tomography (PET) scans in nine patients with prostate cancer. Time-activity curves from the most avid tumor foci were determined. The radiation dose to selected organs was estimated using OLINDA/EXM. Results: No major radiotracer-specific adverse events were observed. Physiologic accumulation was observed in known sites of PSMA expression. Accumulation in putative sites of prostate cancer was observed (SUVmax up to >100, and tumor-to-blood ratios up to >50). The effective radiation dose from [18F]DCFPyL was 0.0139 mGy/MBq or 5 mGy (0.5 rem) from an injected dose of 370 MBq (10 mCi). Conclusions: [18F]DCFPyL is safe with biodistribution as expected, and its accumulation is high in presumed primary and metastatic foci. The radiation dose from [18F]DCFPyL is similar to that from other PET radiotracers.

KW - Fluorine-18

KW - Molecular imaging

KW - PET

KW - PSMA

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84937526847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937526847&partnerID=8YFLogxK

U2 - 10.1007/s11307-015-0850-8

DO - 10.1007/s11307-015-0850-8

M3 - Article

C2 - 25896814

AN - SCOPUS:84937526847

SN - 1536-1632

VL - 17

SP - 565

EP - 574

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

IS - 4

ER -